Invention Grant
- Patent Title: Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
- Patent Title (中): CDK 4/6和FLT3的融合三环双重抑制剂
-
Application No.: US14088796Application Date: 2013-11-25
-
Publication No.: US09359355B2Publication Date: 2016-06-07
- Inventor: Xiaoqi Chen , Kang Dai , Jason Duquette , Michael W. Gribble, Jr. , Justin N. Huard , Kathleen S. Keegan , Zhihong Li , Sarah E. Lively , Lawrence R. McGee , Mark L. Ragains , Xianghong Wang , Margaret F. Weidner , Jian Zhang
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agency: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
- Main IPC: C07D471/14
- IPC: C07D471/14 ; C07D519/00
Abstract:
Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.
Public/Granted literature
- US20140163052A1 FUSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 Public/Granted day:2014-06-12
Information query
